Beruflich Dokumente
Kultur Dokumente
FDA: Guidance on Data Integrity and Compliance with Drug CGMP, December
2018
On 13 December 2018, the US FDA published the final guidance for industry on data integrity. The 17-
page document is structured into 18 Q&A’s and describes the role of data integrity in CGMP for drugs,
as required in 21 CFR parts 210, 211, and 212. Required is a risk-based approach with an effective
strategy for collecting reliable and accurate process data based on process knowledge and empirical
values.
GMP News
Guidance
GMP News
Q&A
The changes compared to the superseded version regard questions 1.20 and 2.21.
1.20 If a pack bearing the safety features is lawfully opened (e.g. by parallel traders/manufacturers
replacing the leaflet under the supervision of national competent authorities), can it be resealed (e.g.
by applying a new ATD on top of the old, broken ATD)?
2.21 Is it acceptable to use stickers to place the unique identifier on the outer/immediate packaging?
GMP News
Q&A
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 1 of 6
GMP Compliance Adviser Member Extras / January 2019 GMP Regulations Report 2018
This 10-page document, once final, will replace the current “Note for guidance on quality of water for
pharmaceutical use” from 2002 and the “CPMP Position Statement on the Quality of Water used in the
production of vaccines for parenteral use".
GMP News
Draft guidance
• Ethylenglycol is now listed with a new PDE of 3.1 mg/day and a concentration limit of
310 ppm (before: 6.2 mg/day and 620 ppm).
Information on the drafting process of the next version (ICH Q3C(R8)) was also announced. The
next update will include PDE levels for three solvents
• 2-methyltetrahydrofuran
• cyclopentylmethylether and
• tert-butanol.
GMP News
ICH Q3C(R7)
The objective of the guidelines is to ensure the quality and identity of pharmaceutical products during
all aspects of the distribution process. These aspects include e.g. procurement, purchasing, storage,
distribution, transportation, documentation and record-keeping practices.
The draft covers the topics well known from other GDP guidelines.
GMP News
CDSCO: GDP-Draft Guideline
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 2 of 6
GMP Compliance Adviser Member Extras / January 2019 GMP Regulations Report 2018
Annex 2 is no longer applicable to Advanced Therapy Medicinal Products to which now applies the
Commission guideline on Good Manufacturing Practice for Advanced Therapy Medicinal Products. The
separate guideline on ATMPs is listed under Part IV of Eudralex Volume 4 and entered into force on 22
May 2018.
GMP News
Eudralex Volume 4, Annex 2
EC: New Annex 17 on Real Time Release Testing and Parametric Release, June
2018
The final version is newly entitled Annex 17: Real Time Release Testing and Parametric Release. The 8-
page document came into force on 26 December 2018 and replaced the preceding version of the year
2002.
Since then, there have been significant changes in GMP consequent to the adoption of the ICH Q8 -
Q11 guidelines and revisions within the EU GMP Guide or the EMA Guideline on RTRT in 2012.
Advances in the application of process analytical technology (PAT), quality by design (QbD) and quality
risk management (QRM) principles to pharmaceutical development and manufacturing have shown
that appropriate combination of process controls together with timely monitoring and verification of
pre-established material attributes provide greater assurance of product quality than end-product
testing alone.
GMP News
Eudralex Volume 4, Annex 17
• Revision 2 of its “Practical guidance for procedures related to Brexit for medicinal products for
marketing authorisation holders (MAH)”
• Q&A document “Q&As related to the UK’s withdrawal from the EU with regard to the
medicinal products for human and veterinary use within the framework of the Centralised
Procedure” (Revision 3).
For the Practical Guidance EMA has added 14 new questions (marked as “NEW”) including who
companies should contact at EMA with Brexit-related inquiries, how to consider national scientific
advice from UK competent authorities and how to transfer orphan designations from UK-based
sponsors to those based in the European Economic Area.
The Q&A document provides procedural and practical guidance regarding submission of changes and
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 3 of 6
GMP Compliance Adviser Member Extras / January 2019 GMP Regulations Report 2018
related fees. Seven new questions were added and some earlier answers updated (marked as “NEW”).
A template containing a standard statement for change of applicant due to Brexit is also provided.
GMP News
Practical Guidance
Q&A
All documents are listed on the “Publications” page of the PIC/S and entered into force on 1 July 2018.
GMP News
PIC/S Publications
In the area of Quality Assurance – GMP this concerns the following documents:
GMP News
52nd TRS1010, WHO
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 4 of 6
GMP Compliance Adviser Member Extras / January 2019 GMP Regulations Report 2018
GMP News
Q&A
GMP News
There has been significant stakeholder interest in the development of the guide. More than 1300
comments were received and taken into consideration. The GXP data integrity guidance has a high
degree of alignment with documents published by other regulators such as PIC/S, WHO, OECD
(guidance and advisory documents on GLP) and EMA. Those documents are also listed as references.
GMP News
GXP data integrity guidance
GMP News
OOS-guidance
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 5 of 6
GMP Compliance Adviser Member Extras / January 2019 GMP Regulations Report 2018
GMP News
Procedural Advice on the Evaluation of ATMPs
Draft guideline for ATMPS
The guidance document “Authorisation of Biosimilars” as well as the corresponding Q&As were
updated accordingly.
GMP News
Guidance
Q&A
www.gmp-publishing.com
© 2019 Maas & Peither AG – GMP Publishing, Schopfheim, all rights reserved. page 6 of 6